Cost-effectiveness of lutetium (177Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden

Table 3 Disutilities for grade 3 and 4 adverse events

Event	Disutility	Ref.
Nausea	0.05	Nafees et al[24]
Vomiting	0.05	Nafees et al[24]
Diarrhea	0.05	Nafees et al[24]
Abdominal pain	0.071	Doyle et al[25]
Thrombocytopenia	0.111	Tolley et al[26]
Lymphopenia	0.111	Assumed2
Leukopenia	0.111	Assumed2
Stomatitis	0.111	Assumed2
Fatigue	0.201	Swinburn et al[27]
Infections	0.111	Assumed2
Asthenia	0.201	Assumed3
Anemia	0.121	Swinburn et al[27]
Pyrexia	0.111	Assumed2
Hyperglycemia	0.111	Assumed2
Neutropenia	0.091	Nafees et al[24]
Hypertension	0.111	Assumed2
Musculoskeletal pain	0.111	Assumed2
Flushing	0.111	Assumed2
Decreased appetite	0.201	Assumed3

¹Standard error assumed to be equal to mean.

²Assumed.

³Assumed to be equal to fatigue.